JP2008110927A - Cosmetic containing royal jelly protein hydrolyzate - Google Patents
Cosmetic containing royal jelly protein hydrolyzate Download PDFInfo
- Publication number
- JP2008110927A JP2008110927A JP2006294233A JP2006294233A JP2008110927A JP 2008110927 A JP2008110927 A JP 2008110927A JP 2006294233 A JP2006294233 A JP 2006294233A JP 2006294233 A JP2006294233 A JP 2006294233A JP 2008110927 A JP2008110927 A JP 2008110927A
- Authority
- JP
- Japan
- Prior art keywords
- royal jelly
- hyaluronic acid
- cosmetics
- skin
- protein hydrolyzate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940109850 royal jelly Drugs 0.000 title claims abstract description 64
- 239000002537 cosmetic Substances 0.000 title claims abstract description 48
- 239000003531 protein hydrolysate Substances 0.000 title claims abstract description 31
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 43
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 43
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 13
- 230000037303 wrinkles Effects 0.000 claims abstract description 13
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 10
- 230000002087 whitening effect Effects 0.000 claims description 8
- 238000005282 brightening Methods 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 108091005804 Peptidases Proteins 0.000 description 24
- 102000035195 Peptidases Human genes 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 235000019833 protease Nutrition 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- -1 face wash Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 4
- 241000257303 Hymenoptera Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- 101710128038 Hyaluronan synthase Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000037330 wrinkle prevention Effects 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- KUPHXIFBKAORGY-UHFFFAOYSA-N 2-amino-3-iodo-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(N)=C1I KUPHXIFBKAORGY-UHFFFAOYSA-N 0.000 description 1
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 102100038779 Arfaptin-2 Human genes 0.000 description 1
- 241000981399 Aspergillus melleus Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000131386 Aspergillus sojae Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000809446 Homo sapiens Arfaptin-2 Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 101710180012 Protease 7 Proteins 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- JZKFHQMONDVVNF-UHFFFAOYSA-N dodecyl sulfate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(O)(=O)=O JZKFHQMONDVVNF-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010043535 protease S Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、ヒアルロン酸産生促進剤を含む化粧料に関し、詳しくは美白、スキンケア、抗老化、美肌、シワ改善/シワ予防、ヒアルロン酸産生促進などの用途に関する。 The present invention relates to a cosmetic containing a hyaluronic acid production promoter, and more particularly to uses such as whitening, skin care, anti-aging, beautiful skin, wrinkle improvement / wrinkle prevention, and hyaluronic acid production promotion.
現在ローヤルゼリーは健康食品、医薬品、化粧品など世界中で広く利用されており、血管拡張、血圧降下、抗菌作用など種々の薬理作用および栄養生理的作用が報告されている。ローヤルゼリーは蜜蜂の唾液腺で合成され、頭部にある下咽頭腺及び大腮腺から分泌されるミルク状の物質で、女王蜂幼虫用の巣房に入れられた幼虫蜂に対して働き蜂が女王蜂を作るために与えるものである。ローヤルゼリーは蛋白質やビタミン、ミネラルをバランスよく含んでおり、これを一生食べ続ける女王蜂は、働き蜂の40倍の寿命と、1日2000個の産卵能力を持つ。このローヤルゼリーの有効成分の研究は、10-ヒドロキシ-2-デセン酸を代表とする脂肪酸、アミノ酸、ビタミンなどの低分子化合物を中心になされてきた。 Currently, royal jelly is widely used around the world, such as health foods, pharmaceuticals, and cosmetics, and various pharmacological and nutritional physiological effects such as vasodilation, blood pressure lowering, and antibacterial effects have been reported. Royal jelly is a milky substance synthesized in the salivary glands of bees and secreted from the hypopharyngeal gland and the large vagina in the head. It is something to give to. Royal jelly contains protein, vitamins, and minerals in a well-balanced manner, and the queen bee that continues to eat it for a lifetime has a life 40 times longer than that of a worker bee and the ability to lay 2000 eggs a day. Research on the active ingredients of this royal jelly has been focused on low molecular weight compounds such as fatty acids, amino acids, vitamins such as 10-hydroxy-2-decenoic acid.
一方、ローヤルゼリーには通常10%以上の蛋白質が含まれているが、この蛋白質の分子構造や生理作用に関する研究は遅れている。また、ローヤルゼリー配合のドリンク剤などの製造時には、アルコール抽出が行われ、蛋白質は沈殿物として分離されるが、この蛋白質の有効利用は図られていないのが現状である。 On the other hand, royal jelly usually contains 10% or more protein, but research on the molecular structure and physiological function of this protein is delayed. Moreover, alcohol is extracted during the production of a drink containing a royal jelly, and the protein is separated as a precipitate. However, at present, the protein is not effectively used.
ローヤルゼリー蛋白質のプロテアーゼ処理物については、カルシウム吸収促進作用(非特許文献1)、血糖値低下作用(非特許文献2)が知られ、抗酸化作用(非特許文献3)、コラーゲン産生促進作用(特許文献1)、降圧作用(特許文献2)についても報告されている。
本発明は、ローヤルゼリー蛋白加水分解物の化粧品用途、特に、美白化粧料、スキンケア化粧料、抗老化化粧料、美肌化粧料、シワ改善/シワ予防用化粧料を提供することを目的とする。 An object of the present invention is to provide a cosmetic application of a royal jelly protein hydrolyzate, in particular, a whitening cosmetic, a skin care cosmetic, an anti-aging cosmetic, a beautiful skin cosmetic, and a wrinkle improving / wrinkle preventing cosmetic.
また、本発明は、ヒアルロン酸産生促進剤を提供することを目的とする。 Another object of the present invention is to provide a hyaluronic acid production promoter.
本発明者は、上記課題に鑑み検討を重ねた結果、ローヤルゼリー素材の蛋白加水分解物が強力なヒアルロン酸産生促進作用を有し、このヒアルロン酸促進作用に基づきスキンケア、美白、抗老化(アンチエージング)、美肌、シワ改善/シワ予防などの種々の効果を有する化粧料が得られることを見出した。 As a result of repeated studies in view of the above problems, the present inventor has found that the protein hydrolyzate of royal jelly material has a strong hyaluronic acid production promoting action, and based on this hyaluronic acid promoting action, skin care, whitening, anti-aging (anti-aging) ), Cosmetics having various effects such as beautiful skin, wrinkle improvement / wrinkle prevention, etc. were found.
本発明は、以下のヒアルロン酸産生促進剤、美白化粧料、スキンケア化粧料、抗老化化粧料、美肌化粧料、シワ改善/シワ予防化粧料を提供するものである。
1. ローヤルゼリー素材の蛋白加水分解物を含むヒアルロン酸産生促進剤。
2. 項1に記載のヒアルロン酸産生促進剤を含む美白化粧料。
3. 項1に記載のヒアルロン酸産生促進剤を含むスキンケア化粧料。
4. 項1に記載のヒアルロン酸産生促進剤を含む抗老化化粧料。
5. 項1に記載のヒアルロン酸産生促進剤を含む美肌化粧料。
6. 項1に記載のヒアルロン酸産生促進剤を含むシワを改善ないし予防する化粧料。
The present invention provides the following hyaluronic acid production promoter, whitening cosmetics, skin care cosmetics, anti-aging cosmetics, skin beautifying cosmetics, wrinkle improving / wrinkle preventing cosmetics.
1. Hyaluronic acid production promoter containing protein hydrolyzate of royal jelly material.
2. Item 2. A whitening cosmetic comprising the hyaluronic acid production promoter according to Item 1.
3. Item 11. A skin care cosmetic comprising the hyaluronic acid production promoter according to Item 1.
4). Item 6. An anti-aging cosmetic comprising the hyaluronic acid production promoter according to Item 1.
5. Item 1. A skin beautifying cosmetic comprising the hyaluronic acid production promoter according to Item 1.
6). A cosmetic for improving or preventing wrinkles comprising the hyaluronic acid production promoter according to Item 1.
本発明によれば、ローヤルゼリー蛋白加水分解物を含む化粧料を肌に適用することで、しみ、くすみ、肌荒れ、しみ、たるみなどの肌に関するトラブルを解決することができる。 ADVANTAGE OF THE INVENTION According to this invention, the trouble regarding skin, such as a spot, dullness, rough skin, a spot, sagging, can be solved by applying the cosmetics containing a royal jelly protein hydrolyzate to skin.
本発明において、蛋白質の原料となるローヤルゼリー素材としては、ローヤルゼリーの蛋白質を含む素材を意味するものであり、この要件を満たしていれば特に限定されず、例えば生ローヤルゼリー、乾燥ローヤルゼリー、ローヤルゼリーをエタノール沈殿、硫安処理、加熱処理等の蛋白変性処理を行って得られた蛋白沈殿物(エタノール沈殿物を含む)、或いは、ローヤルゼリーを抽出、濾過、遠心分離、クロマトグラフィー等の種々の手段により分画後の蛋白質を含む素材を意味する。 In the present invention, the royal jelly material used as a protein raw material means a material containing the protein of royal jelly, and is not particularly limited as long as this requirement is satisfied. For example, raw royal jelly, dried royal jelly, royal jelly is ethanol precipitated. Protein fraction obtained by protein denaturation treatment such as ammonium sulfate treatment and heat treatment (including ethanol precipitate) or royal jelly is extracted, filtered, centrifuged, chromatographed, etc. Means a material containing protein.
ローヤルゼリーは、いかなるものであってもよく、女王蜂を育てるために蜜蜂が分泌するものを広く用いることができる。具体的には、ローヤルゼリーは、蜜蜂のうち働き蜂が下咽頭腺及び大腮腺から分泌する分泌物を混合してつくる乳白色のゼリー状物質である。
ローヤルゼリー由来の蛋白質分画としては、ローヤルゼリーをアルコール沈殿して採取した蛋白分画を好適に用いることができる。特にローヤルゼリー飲料の製造時に水不溶性蛋白として副生するローヤルゼリーのエタノール変性蛋白質を使用するのが好ましい。エタノール変性蛋白質は、50〜100容量%程度のエタノールを使用してローヤルゼリーからデセン酸等の飲料用の生理活性物質を抽出した残渣の水に対する溶解度が小さい蛋白質として得ることができる。
The royal jelly may be anything, and widely used by bees secreted to grow queen bees. Specifically, the royal jelly is a milky white jelly-like substance produced by mixing secreted products of the bees from the hypopharyngeal gland and the greater vagina.
As the protein fraction derived from royal jelly, a protein fraction obtained by alcohol precipitation of royal jelly can be preferably used. In particular, it is preferable to use an ethanol-denatured protein of royal jelly that is by-produced as a water-insoluble protein during the production of a royal jelly beverage. The ethanol-denatured protein can be obtained as a protein having a low solubility in water of a residue obtained by extracting a physiologically active substance for beverages such as decenoic acid from royal jelly using about 50 to 100% by volume of ethanol.
本発明のローヤルゼリー素材の加水分解物は、蛋白質分解酵素により加水分解を行うことにより得ることができる。蛋白質分解酵素には、エンドペプチダーゼとエキソペプチダーゼが含まれ、これらの1種または2種以上を使用することができる。 The hydrolyzate of the royal jelly material of the present invention can be obtained by performing hydrolysis with a proteolytic enzyme. Proteolytic enzymes include endopeptidases and exopeptidases, and one or more of these can be used.
本発明で使用する蛋白質分解酵素としては、動物由来(例えば、トリプシン、キモトリプシン、ペプシン、パンクレアチン等)、植物由来(例えば、パパイン等)、又は微生物由来(例えば、乳酸菌、酵母、カビ、枯草菌、放線菌等)のエンドペプチダーゼ、カルボキシペプチダーゼ、アミノペプチダーゼ、若しくは微生物由来(例えば、乳酸菌、アスペルギルス属菌、リゾープス属菌等)等のエキソペプチダーゼを例示することができる。 The proteolytic enzyme used in the present invention is derived from animals (for example, trypsin, chymotrypsin, pepsin, pancreatin, etc.), derived from plants (for example, papain, etc.), or derived from microorganisms (for example, lactic acid bacteria, yeast, mold, Bacillus subtilis). And exopeptidases derived from microorganisms (eg, lactic acid bacteria, Aspergillus, Rhizopus, etc.).
蛋白質分解酵素の好ましい例としては、例えばストレプトマイセス・グリセウス(Streptomyces griseus)産生ペプチダーゼ(商品名:アクチナーゼAS)、アスペルギルス・オリゼー(Aspergillus oryzae)産生ペプチダーゼ(商品名:プロテアーゼA、フレーバーザイム)、アスペルギルス・メレウス(Aspergillus melleus)産生ペプチダーゼ(商品名:プロテアーゼP)、アスペルギルス・オリゼー(Aspergillus oryzae)産生ペプチダーゼ(商品名:ウマミザイムG、Promod 192P、Promod 194P、スミチームFLAP)、アスペルギルス・ソーエ(Aspergillus sojae)産生ペプチダーゼ(商品名:Sternzyme B15024)、アスペルギルス属産生ペプチダーゼ(商品名:コクラーゼP)、リゾプス・オリゼー(Rhizopus oryzae)産生ペプチダーゼ(商品名:ペプチダーゼR)、バチルス・サブチリス(Bacillus subtilis)産生ペプチダーゼ(商品名:オリエンターゼ22BF、ヌクレイシン)、バチルス・リシェニフォルミス(Bacillus licheniformis)産生ペプチダーゼ(商品名:アルカラーゼ)、バチルス・ステアロサーモフィラス(Bacillus stearothermophilus)産生ペプチダーゼ(商品名:プロテアーゼS)、バチルス・アミロリケファシエンス(Bacillus amyloliquefaciens)産生ペプチダーゼ(商品名:ニュートラーゼ)、バチルス属産生ペプチダーゼ(商品名:プロタメックス)を挙げることができる。 Preferable examples of the proteolytic enzyme include, for example, Streptomyces griseus-produced peptidase (trade name: actinase AS), Aspergillus oryzae-produced peptidase (trade name: protease A, flavorzyme), Aspergillus・ Production of peptidase from Aspergillus melleus (trade name: Protease P), production of peptidase from Aspergillus oryzae (trade name: Ummamizyme G, Promod 192P, Promod 194P, Sumiteam FLAP), production of Aspergillus sojae Peptidase (trade name: Sternzyme B15024), Aspergillus genus peptidase (trade name: cochlase P), Rhizopus oryzae peptidase (trade name: peptidase R), Bacillus subtilis (Baci) llus subtilis-produced peptidase (trade name: orientase 22BF, nucleisin), Bacillus licheniformis-produced peptidase (trade name: Alcalase), Bacillus stearothermophilus-produced peptidase (product) Name: Protease S), Bacillus amyloliquefaciens production peptidase (trade name: Neutase), Bacillus genus peptidase (trade name: Protamex).
さらに、蛋白質分解酵素に1以上のアミノ酸を置換、付加、欠失、挿入等により改変した変異型酵素を使用してもよい。このような変異型蛋白質分解酵素も本発明のローヤルゼリー素材の酵素分解に使用される。 Furthermore, a mutant enzyme in which one or more amino acids are substituted, added, deleted, inserted, or the like may be used for the proteolytic enzyme. Such a mutant proteolytic enzyme is also used for enzymatic degradation of the royal jelly material of the present invention.
ローヤルゼリー素材を蛋白質分解酵素で処理する条件としては、例えば、水性溶媒中約15℃から約60℃、好ましくは約20℃から約50℃、特に37℃前後で、1〜72時間程度、好ましくは3〜48時間程度処理することにより好ましく実施することができる。蛋白質分解酵素の使用量は、例えば蛋白質100g当たり0.01〜3g程度、好ましくは0.05〜1g程度である。蛋白質分解酵素は遊離の酵素を用いてもよく、担体に固定化した酵素を使用してもよい。 The conditions for treating the royal jelly material with a proteolytic enzyme include, for example, about 15 ° C. to about 60 ° C., preferably about 20 ° C. to about 50 ° C., particularly around 37 ° C. in an aqueous solvent, preferably about 1 to 72 hours, preferably It can implement preferably by processing for about 3 to 48 hours. The amount of proteolytic enzyme used is, for example, about 0.01 to 3 g, preferably about 0.05 to 1 g, per 100 g of protein. As the proteolytic enzyme, a free enzyme may be used, or an enzyme immobilized on a carrier may be used.
反応液は水を好適に使用できるが、少量のエタノール等の水混和性有機溶媒を含む、含水エタノール等の水性溶媒中で行ってもよい。 Water can be suitably used for the reaction solution, but it may be carried out in an aqueous solvent such as hydrous ethanol containing a small amount of a water-miscible organic solvent such as ethanol.
酵素分解物の反応液は、加熱処理、必要に応じてさらに遠心分離、濾過、抽出、脱塩、凍結乾燥やスプレードライ(または、噴霧乾燥)などの後処理を行い、蛋白分解物を得ることができる。例えば、ローヤルゼリー素材として生ローヤルゼリー或いは乾燥ローヤルゼリーを使用した場合、ローヤルゼリー由来の糖質等の成分を除去することもできる。 The reaction solution of the enzymatic degradation product is subjected to heat treatment, and if necessary, post-treatment such as centrifugation, filtration, extraction, desalting, freeze drying or spray drying (or spray drying) to obtain a protein degradation product. Can do. For example, when raw royal jelly or dried royal jelly is used as the royal jelly material, components such as saccharides derived from royal jelly can be removed.
本発明の好ましい実施形態の1つにおいて、本発明のローヤルゼリー素材の蛋白分解物は、ゲル濾過カラムにより測定された平均分子量が300〜7000程度、特に500〜6000程度を有する。 In one preferred embodiment of the present invention, the royal jelly material proteolysate of the present invention has an average molecular weight of about 300 to 7000, particularly about 500 to 6000, as measured by a gel filtration column.
本発明の蛋白分解物は、酵素処理後に必要に応じて脱塩処理をして製造してもよく、さらにカラムなどの処理によりヒアルロン酸産生促進作用がより強い分画を集めることも可能である。 The proteolysate of the present invention may be produced by desalting as necessary after enzyme treatment, and it is also possible to collect fractions having a stronger hyaluronic acid production promoting effect by treatment with a column or the like. .
本発明におけるローヤルゼリー蛋白加水分解物の配合量は、化粧料全量中、乾燥物として0.0005〜20.0重量%、好ましくは0.001〜10.0重量%である。0.0005重量%未満であると、本発明の効果が十分に発揮されず、20.0重量%を超えると製剤化が難しいので好ましくない。また、10.0重量%以上配合してもさほど大きな効果の向上はみられない。さらに、ローヤルゼリーの蛋白加水分解物は0.01〜0.1重量%の濃度で肌に適用するのが特に好ましい。 The compounding quantity of the royal jelly protein hydrolyzate in this invention is 0.0005 to 20.0 weight% as a dry substance in the cosmetics whole quantity, Preferably it is 0.001 to 10.0 weight%. If it is less than 0.0005% by weight, the effect of the present invention is not sufficiently exhibited, and if it exceeds 20.0% by weight, it is difficult to make a preparation. Moreover, even if it mix | blends 10.0 weight% or more, the improvement of the big effect is not seen. Furthermore, the royal jelly protein hydrolyzate is particularly preferably applied to the skin at a concentration of 0.01 to 0.1% by weight.
ヒアルロン酸は、真皮繊維芽細胞の膜に存在するヒアルロン酸合成酵素(HAS)によって合成される酸性ムコ多糖である(Y. Sugiyama ら J. Invest. Dermatol., 110, 116(1998))。ヒアルロン酸は細胞間隙への水分の保持、組織内にゼリー状のマトリックスを形成することに基づく細胞の保持、組織の潤滑性と柔軟性の保持に寄与している(BIOINDUSTRY Vol8, 346(1991))。ヒアルロン酸は加齢に伴い減少(K. Matsuokaら Aging, 1, 47(1989))、あるいは変性することが報告されており(L.A.M.Meyer ら J. Invest. Dermatol., 102, 385(1994))、このような変化が肌の乾燥、シワ、たるみなどを引き起こす一因となっているといわれている。 Hyaluronic acid is an acidic mucopolysaccharide synthesized by hyaluronic acid synthase (HAS) present in the membrane of dermal fibroblasts (Y. Sugiyama et al., J. Invest. Dermatol., 110, 116 (1998)). Hyaluronic acid contributes to retention of water in the cell gap, retention of cells based on the formation of a jelly-like matrix in the tissue, and maintenance of tissue lubricity and flexibility (BIOINDUSTRY Vol8, 346 (1991) ). Hyaluronic acid has been reported to decrease with age (K. Matsuoka et al. Aging, 1, 47 (1989)) or to denature (LAMMeyer et al. J. Invest. Dermatol., 102, 385 (1994)) Such changes are said to contribute to dry skin, wrinkles, sagging and the like.
本発明に用いられるローヤルゼリー蛋白加水分解物は、いずれもヒトの肌に対して優れたヒアルロン酸産生促進作用を有するので、該加水分解物が配合された化粧料は、肌にはりと潤いを与え、肌の老化を防ぎ、シワをなくし若しくは軽減し、肌をみずみずしくしてシミやくすみを目立たなくし、美肌効果を有し、健康な肌を維持できるため、美白化粧料、抗老化化粧料、美肌化粧料、スキンケア化粧料、シワを改善/予防用化粧料などとして有用である。 Since the royal jelly protein hydrolyzate used in the present invention has an excellent hyaluronic acid production promoting action on human skin, the cosmetics containing the hydrolyzate give skin elasticity and moisture. , Prevents skin aging, eliminates or reduces wrinkles, makes skin fresh, makes spots and dullness unnoticeable, has a beautifying effect, and maintains healthy skin, whitening cosmetics, anti-aging cosmetics, beautiful skin It is useful as cosmetics, skin care cosmetics, wrinkle improving / preventing cosmetics, and the like.
本発明の化粧料には、ローヤルゼリー蛋白加水分解物以外に、通常化粧品に用いられる成分、例えば、美白剤、保湿剤、酸化防止剤、油性成分、紫外線吸収剤、界面活性剤、増粘剤、アルコール類、粉末成分、色材、水性成分、水、各種皮膚栄養剤等を必要に応じて適宜配合することができる。 In addition to the royal jelly protein hydrolyzate, the cosmetics of the present invention include components usually used in cosmetics, such as whitening agents, moisturizers, antioxidants, oily components, ultraviolet absorbers, surfactants, thickeners, Alcohols, powder components, color materials, aqueous components, water, various skin nutrients, and the like can be appropriately blended as necessary.
本発明の化粧料の剤型は、水溶液系、可溶化系、乳化系、粉末系、油液系、ゲル系、軟膏系、エアゾール系、水−油2層系、水−油−粉末3層系等、幅広い剤型を採り得る。例えば基礎化粧品であれば、洗顔料、化粧水、乳液、クリーム、ジェル、エッセンス、美容液、パック、マスク等が挙げられ、メークアップ化粧品であれば、ファンデーション、口紅、頬紅、アイシャドウ、アイライナー、マスカラなどが挙げられ、その他、洗顔料、マッサージ用剤、クレンジング用剤、アフターシェーブローション、プレシェーブローション、シェービングクリーム、ボディソープ、石けん、シャンプー、リンス、ヘアートリートメント、整髪料、ヘアートニック剤、育毛剤、制汗剤、衛生用品等が挙げられる。 The cosmetic dosage form of the present invention includes an aqueous solution system, a solubilization system, an emulsification system, a powder system, an oil liquid system, a gel system, an ointment system, an aerosol system, a water-oil two-layer system, and a water-oil-powder three-layer system. A wide range of dosage forms can be adopted. For example, for basic cosmetics, face wash, lotion, milky lotion, cream, gel, essence, beauty liquid, pack, mask, etc., for makeup cosmetics, foundation, lipstick, blusher, eye shadow, eyeliner , Mascara, etc., facial cleanser, massage agent, cleansing agent, after shave lotion, pre-shave lotion, shaving cream, body soap, soap, shampoo, rinse, hair treatment, hair conditioner, hair art agent, hair restorer Antiperspirants, hygiene products and the like.
以下、本発明を実施例により説明するが、本実施例によって本発明が限定されるものではない。
製造例1
生ローヤルゼリー250gを500mLのビーカーに量りとり、イオン交換水20mLを加え、均一になるまで攪拌した。2N NaOHを47mL添加し、pH8.7に調整した。酵素BP (SternzymeBP14202; SternEnzyme社製 Bacillus subtilis由来のbacillolysin)2.5gを添加し、さらにイオン交換水33mLを加え均一になるまで攪拌した。ビーカーを恒温水槽に浸け、ローヤルゼリー液をスリーワンモーターで攪拌しながら、45℃にて15時間反応させた。恒温水槽の温度を上げ、ローヤルゼリー液をスリーワンモーターで攪拌しながら加熱し、80℃に到達後直ちに水冷し、凍結乾燥して、ローヤルゼリー蛋白加水分解物を凍結乾燥物として得た。
EXAMPLES Hereinafter, although an Example demonstrates this invention, this invention is not limited by this Example.
Production Example 1
250 g of fresh royal jelly was weighed into a 500 mL beaker, 20 mL of ion exchange water was added, and the mixture was stirred until uniform. 47 mL of 2N NaOH was added and adjusted to pH 8.7. 2.5 g of enzyme BP (SternzymeBP14202; bacilillolysin derived from Bacillus subtilis manufactured by SternEnzyme) was added, and 33 mL of ion-exchanged water was further added and stirred until uniform. The beaker was immersed in a constant temperature water bath and reacted at 45 ° C. for 15 hours while stirring the royal jelly solution with a three-one motor. The temperature of the thermostatic bath was raised and the royal jelly solution was heated while stirring with a three-one motor. After reaching 80 ° C., the mixture was immediately cooled with water and freeze-dried to obtain a royal jelly protein hydrolyzate as a lyophilized product.
実施例1:ヒアルロン酸産生促進(in vitro)
ヒト正常線維芽細胞樹立株WI-38細胞を10%FCS(ウシ胎児血清)含有RPMI-1640培地で、1×105細胞/mlに調整し(細胞懸濁液)、1ウェル当たり細胞懸濁液100μlを加えた。次いで、このプレートを37℃で終夜、5%CO2-95%空気中で培養し、RPMI-1640培地150μlとPBS(-)40μlの混合物で培地交換し、製造例1で得たローヤルゼリー蛋白加水分解物を100μg/mL(最終濃度)になるように各ウェルに添加し、37℃で48時間、5%CO2-95%空気中で培養した。培養物を1500rpmで15分間遠心し、上清を得た。得られた上清中のヒアルロン酸量を市販のヒアルロン酸測定キット(生化学工業製)を用いて測定した。
Example 1: Promotion of hyaluronic acid production (in vitro)
Normal human fibroblast cell line WI-38 cells were adjusted to 1 × 10 5 cells / ml with 10% FCS (fetal bovine serum) -containing RPMI-1640 medium (cell suspension), and cell suspension per well 100 μl of the solution was added. Then, this plate was incubated overnight at 37 ° C. in 5% CO 2 -95% air, and the medium was changed with a mixture of 150 μl of RPMI-1640 medium and 40 μl of PBS (−), and the royal jelly protein hydrolyzed protein obtained in Production Example 1 was replaced. The degradation product was added to each well to a concentration of 100 μg / mL (final concentration), and incubated at 37 ° C. for 48 hours in 5% CO 2 -95% air. The culture was centrifuged at 1500 rpm for 15 minutes to obtain a supernatant. The amount of hyaluronic acid in the obtained supernatant was measured using a commercially available hyaluronic acid measurement kit (Seikagaku Corporation).
また、製造例1で得たローヤルゼリー蛋白加水分解物に代えて未処理の生ローヤルゼリー凍結乾燥物、あるいはこれらのコントロール群についても同様に、上清中のヒアルロン酸濃度を測定した。ヒアルロン酸産生促進率は、サンプルの代わりに水を0.01ml添加した場合のヒアルロン酸量を100として算出した。結果を表1に示す。 In addition, the hyaluronic acid concentration in the supernatant was measured in the same manner for the untreated raw royal jelly lyophilizate instead of the royal jelly protein hydrolyzate obtained in Production Example 1 or for these control groups. The hyaluronic acid production promotion rate was calculated with the amount of hyaluronic acid when 0.01 ml of water was added instead of the sample being 100. The results are shown in Table 1.
表1の結果から、本発明のローヤルゼリー蛋白加水分解物は、ヒト細胞について優れたヒアルロン酸産生促進作用を有することが明らかになった。 From the results in Table 1, it was revealed that the royal jelly protein hydrolyzate of the present invention has an excellent hyaluronic acid production promoting action for human cells.
実施例2:ヒアルロン酸産生促進(in vivo)
ヘアレスマウス(Hos:hr-1)の皮膚にローヤルゼリー蛋白質加水分解物の水溶液並びに基剤(水、コントロール)を2週間、100μl/5cm2 /匹/日で塗布し、最終塗布24時間後に皮膚を採取した。採取したヘアレスマウスの皮膚を以下に示す方法で処理することにより、皮膚中のヒアルロン酸の定量を行った。
Example 2: Promotion of hyaluronic acid production (in vivo)
An aqueous solution of a royal jelly protein hydrolyzate and a base (water, control) were applied to the skin of a hairless mouse (Hos: hr-1) for 2 weeks at 100 μl / 5 cm 2 / animal / day, and the skin was applied 24 hours after the final application. Collected. The collected skin of hairless mice was treated by the following method to determine the amount of hyaluronic acid in the skin.
ヒアルロン酸の定量は、以下のように行った。 Hyaluronic acid was quantified as follows.
アセトンで脱脂したマウス皮膚を細切した後、アルカリ処理、中和、プロナーゼE(シグマ)処理、さらに、トリクロロ酢酸処理および透析(Spectra/POR1、分画分子量6000〜8000、Spectrum社製)を行い、ヒアルロン酸の定量用のサンプルを調製した。ヒアルロン酸の定量は、ビオチン標識ヒアルロン酸結合性蛋白(生化学工業社製)を用いたELISA法(A.J.Fosanget al.,Matrix,10,306−313,1990)で行った。なお、皮膚のヒアルロン酸含量の指標として、コントロールに対する乾燥皮膚重量あたりのヒアルロン酸含量(相対値%)を用いた。 Mouse skin degreased with acetone is cut into small pieces, then subjected to alkali treatment, neutralization, pronase E (Sigma) treatment, trichloroacetic acid treatment and dialysis (Spectra / POR1, fractional molecular weight 6000 to 8000, manufactured by Spectrum). A sample for quantitative determination of hyaluronic acid was prepared. Hyaluronic acid was quantified by ELISA (AJ Fosang et al., Matrix, 10, 306-313, 1990) using biotin-labeled hyaluronic acid binding protein (Seikagaku Corporation). The hyaluronic acid content (relative value%) per dry skin weight relative to the control was used as an index of the skin hyaluronic acid content.
上記の試験の結果、ローヤルゼリー蛋白質加水分解物は皮膚のヒアルロン酸産生を促進し、特に10〜100μg/mlの濃度で高い効果を得られることが明らかとなった。
処方例1:化粧水
化粧水を以下の処方に基づき、常法によって調製した。なお、ローヤルゼリー蛋白加水分解物としては、上記の製造例1で調製されたものを用いた。
化粧水の処方
組成 配合量(%)
エタノール 10.00
ソルビット液 5.00
メチルパラベン 0.05
トリポリオキシエチレンエーテルリン酸 0.40
ローヤルゼリー蛋白加水分解物 0.01
クエン酸 0.02
クエン酸ナトリウム 0.05
精製水 残量
(合計) 100.00
As a result of the above test, it was found that the royal jelly protein hydrolyzate promotes the production of hyaluronic acid in the skin, and a high effect can be obtained particularly at a concentration of 10 to 100 μg / ml.
Formulation Example 1: Lotion Toner lotion was prepared by a conventional method based on the following formulation. In addition, what was prepared in said manufacture example 1 was used as a royal jelly protein hydrolyzate.
Toner lotion composition Composition amount (%)
Ethanol 10.00
Sorbit solution 5.00
Methylparaben 0.05
Tripolyoxyethylene ether phosphate 0.40
Royal jelly protein hydrolyzate 0.01
Citric acid 0.02
Sodium citrate 0.05
Purified water remaining
(Total) 100.00
処方例2:美容液
美容液を以下の処方に基づき、常法によって調製した。なお、ローヤルゼリー蛋白加水分解物としては、上記の製造例1で調製されたものを用いた。
美容液の処方
組成 配合量(%)
エタノール 8.00
1,3ブチレングリコール 5.00
メチルパラベン 0.10
ポリオキシエチレンセチルエーテル 0.20
ローヤルゼリー蛋白加水分解物 0.05
キサンタンガム 0.05
ヒドロキシエチルセルロース 0.10
エデト酸2ナトリウム 0.01
精製水 残量
(合計) 100.00
Formulation Example 2: Cosmetic liquid A cosmetic liquid was prepared by a conventional method based on the following formulation. In addition, what was prepared in said manufacture example 1 was used as a royal jelly protein hydrolyzate.
Cosmetic liquid prescription composition
Ethanol 8.00
1,3 Butylene glycol 5.00
Methylparaben 0.10
Polyoxyethylene cetyl ether 0.20
Royal jelly protein hydrolyzate 0.05
Xanthan gum 0.05
Hydroxyethyl cellulose 0.10
Edetic acid disodium 0.01
Purified water remaining
(Total) 100.00
処方例3:シャンプー
シャンプーを以下の処方に基づき、常法によって調製した。なお、ローヤルゼリー蛋白加水分解物としては、上記の製造例1で調製されたものを用いた。
組成 配合量(%)
ラウリル硫酸トリエタノールアミン 20.00
ポリオキシエチレンラウリルエーテル硫酸ナトリウム 10.00
アルキル硫酸ナトリウム液 10.00
ヤシ油脂肪酸アミドプロピルベタイン液 10.00
ポリオキシエチレンラウリルエーテル 1.00
ヤシ油脂肪酸ジエタノールアミド 3.00
ヤシ油脂肪酸モノエタノールアミド 0.45
ジステアリン酸エチレングリコール 0.50
メチルパラベン 0.10
グリセリン 5.00
塩化O−[2−ヒドロキシ−3−(トリメチルアンモニオ)
プロピル]ヒドロキシエチルセルロース 0.20
ポリオキシエチレン・メチルポリシロキサン共重合体 0.10
ローヤルゼリー蛋白加水分解物 0.05
精製水 残量
(合計) 100.00
Formulation Example 3: Shampoo Shampoo was prepared by a conventional method based on the following formulation. In addition, what was prepared in said manufacture example 1 was used as a royal jelly protein hydrolyzate.
Composition Blending amount (%)
Lauryl sulfate triethanolamine 20.00
Sodium polyoxyethylene lauryl ether sulfate 10.00
Sodium alkyl sulfate solution 10.00
Palm oil fatty acid amidopropyl betaine solution 10.00
Polyoxyethylene lauryl ether 1.00
Coconut oil fatty acid diethanolamide 3.00
Palm oil fatty acid monoethanolamide 0.45
Ethylene glycol distearate 0.50
Methylparaben 0.10
Glycerin 5.00
O- [2-hydroxy-3- (trimethylammonio) chloride
Propyl] hydroxyethyl cellulose 0.20
Polyoxyethylene / methylpolysiloxane copolymer 0.10
Royal jelly protein hydrolyzate 0.05
Purified water remaining
(Total) 100.00
処方例4:乳液
乳液を以下の処方に基づき、常法によって調製した。なお、ローヤルゼリー蛋白加水分解物としては、上記の製造例1で調製されたものを用いた。
組成 配合量(%)
軟質ラノリン脂肪酸コレステリル 10.00
POE(20)ソルビタンモノステアレート 1.80
モノステアリン酸グリセリン 1.20
ローヤルゼリー蛋白加水分解物 0.10
グリセリン 3.00
メチルパラベン 0.10
エチルパラベン 0.10
香料 適 量
精製水 残 量
(合計) 100.00
Formulation Example 4: Emulsion An emulsion was prepared by a conventional method based on the following formulation. In addition, what was prepared in said manufacture example 1 was used as a royal jelly protein hydrolyzate.
Composition Blending amount (%)
Soft lanolin fatty acid cholesteryl 10.00
POE (20) sorbitan monostearate 1.80
Glycerol monostearate 1.20
Royal Jelly Protein Hydrolyzate 0.10
Glycerin 3.00
Methylparaben 0.10
Ethylparaben 0.10
Perfume appropriate amount
Purified water balance
(Total) 100.00
処方例5:クリーム
クリームを以下の処方に基づき、常法によって調製した。なお、ローヤルゼリー蛋白加水分解物としては、上記の製造例1で調製されたものを用いた。
組成 配合量(%)
マカデミアンナッツ油脂肪酸コレステリル 10.00
ステアリン酸 7.50
セトステアリルアルコール 1.50
トリイソオクタン酸グリセリン 12.00
ラノリン 3.00
パルミチン酸セチル 4.00
モノステアリン酸PEG(40) 2.00
モノステアリン酸グリセリン 5.00
ローヤルゼリー蛋白加水分解物 0.10
防腐剤 適量
酸化防止剤 適量
香料 適量
精製水 残量
(合計) 100.00
Formulation Example 5: Cream A cream was prepared by a conventional method based on the following formulation. In addition, what was prepared in said manufacture example 1 was used as a royal jelly protein hydrolyzate.
Composition Blending amount (%)
Macadamia nut oil fatty acid cholesteryl 10.00
Stearic acid 7.50
Cetostearyl alcohol 1.50
Triisooctanoic acid glycerin 12.00
Lanolin 3.00
Cetyl palmitate 4.00
PEG monostearate (40) 2.00
Glycerol monostearate 5.00
Royal Jelly Protein Hydrolyzate 0.10
Preservative Appropriate amount Antioxidant Appropriate amount Fragrance Appropriate amount
Purified water remaining
(Total) 100.00
試験例
処方例1で得た化粧水(本発明)と、ローヤルゼリー蛋白加水分解物を含まない以外は同一の組成を有する化粧水(コントロール)について、パネラー10名により、保湿作用(しっとり感)、美白作用(くすみの改善)、抗老化(しわの改善)、美肌作用(肌のはり、つや)の4項目について試験した。
Test Example About the lotion obtained in Formulation Example 1 (invention) and the lotion having the same composition except that it does not contain the royal jelly protein hydrolyzate (control), 10 panelists gave moisturizing action (moist feeling), Four items of whitening action (improvement of dullness), anti-aging (improvement of wrinkles), and beautification action (skin tension, gloss) were tested.
その結果、ローヤルゼリー蛋白加水分解物を含む本発明の化粧水は、該加水分解物を含まないコントロールの化粧水と比較して、全ての項目について高い評価を得た。 As a result, the lotion of the present invention containing the royal jelly protein hydrolyzate was highly evaluated for all items as compared with the control lotion containing no hydrolyzate.
また、データは示さないが、上記4項目の評価の向上は、パネラーにおけるヒアルロン酸量の増加と関係があり、これらの評価の向上は、ヒアルロン酸産生促進作用に基づくことが明らかになった。 Moreover, although data are not shown, it became clear that the improvement of the evaluation of the above four items is related to the increase in the amount of hyaluronic acid in the panelists, and the improvement of these evaluations is based on the hyaluronic acid production promoting action.
Claims (6)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006294233A JP2008110927A (en) | 2006-10-30 | 2006-10-30 | Cosmetic containing royal jelly protein hydrolyzate |
| CNA2007101851449A CN101172095A (en) | 2006-10-30 | 2007-10-30 | Cosmetics material of protolysate containing royal jelly |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006294233A JP2008110927A (en) | 2006-10-30 | 2006-10-30 | Cosmetic containing royal jelly protein hydrolyzate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008110927A true JP2008110927A (en) | 2008-05-15 |
Family
ID=39420989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006294233A Pending JP2008110927A (en) | 2006-10-30 | 2006-10-30 | Cosmetic containing royal jelly protein hydrolyzate |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2008110927A (en) |
| CN (1) | CN101172095A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011162476A (en) * | 2010-02-09 | 2011-08-25 | Maruzen Pharmaceut Co Ltd | SERINE PALMITOYLTRANSFERASE mRNA EXPRESSION PROMOTER AND AQUAPORIN 3 mRNA EXPRESSION PROMOTER |
| JP2012067061A (en) * | 2010-09-27 | 2012-04-05 | Maruzen Pharmaceut Co Ltd | Maillard reaction inhibitor and aging improving agent |
| JP2012140376A (en) * | 2010-12-29 | 2012-07-26 | Kracie Home Products Ltd | Tyrosinase activity inhibitor, melanin production inhibitor and beautifying and whitening agent, and cosmetic, food and drink composition and pharmaceutical composition each containing them |
| JP2013221017A (en) * | 2012-04-17 | 2013-10-28 | Api Co Ltd | Epidermal cell activator, cosmetic including the same, skin care external preparation and anti-wrinkle cosmetic |
| EP2316417A3 (en) * | 2009-09-03 | 2014-08-06 | Henkel AG & Co. KGaA | Non-therapeutic use to prevent skin aging |
| JP2016503781A (en) * | 2012-12-21 | 2016-02-08 | ロレアル | C-xyloside compound, composition thereof and use thereof for depigmenting skin |
| JP2019006731A (en) * | 2017-06-27 | 2019-01-17 | 小林製薬株式会社 | Skin cleanser composition |
| JPWO2021015233A1 (en) * | 2019-07-23 | 2021-01-28 | ||
| JP2025078258A (en) * | 2023-11-08 | 2025-05-20 | 株式会社山田養蜂場本社 | Dermis thickness improving agent, skin texture improving agent, and cosmetic product for improving dermis thickness or skin texture |
| JP2025078199A (en) * | 2023-11-08 | 2025-05-20 | 株式会社山田養蜂場本社 | Skin flora improving agent and skin flora improving cosmetic |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105380816B (en) * | 2015-12-14 | 2019-04-30 | 北京肽康生物科技有限公司 | Purposes of the biologically active peptide in cosmetics preparation |
| FR3061017B1 (en) * | 2016-12-22 | 2020-03-20 | L V M H Recherche | COSMETIC COMPOSITION COMPRISING ROYAL BLACK BEE JELLY OF OUESSANT |
| CN108283617A (en) * | 2018-04-24 | 2018-07-17 | 上海上水和肌化妆品有限公司 | A kind of composition and forming method of skin basement membrane maintenance |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002020226A (en) * | 2000-06-30 | 2002-01-23 | Katakura Chikkarin Co Ltd | Cosmetic composition |
| JP2003171258A (en) * | 2001-12-06 | 2003-06-17 | Katakura Chikkarin Co Ltd | Cosmetic composition |
| JP2006219434A (en) * | 2005-02-10 | 2006-08-24 | Kyoei Kagaku Kogyo Kk | Cosmetics |
| JP2006225269A (en) * | 2005-02-15 | 2006-08-31 | Yoshihiro Futamura | Tripeptide having collagenase inhibition, fermentation product, food preparation and cosmetic preparation containing the same |
-
2006
- 2006-10-30 JP JP2006294233A patent/JP2008110927A/en active Pending
-
2007
- 2007-10-30 CN CNA2007101851449A patent/CN101172095A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002020226A (en) * | 2000-06-30 | 2002-01-23 | Katakura Chikkarin Co Ltd | Cosmetic composition |
| JP2003171258A (en) * | 2001-12-06 | 2003-06-17 | Katakura Chikkarin Co Ltd | Cosmetic composition |
| JP2006219434A (en) * | 2005-02-10 | 2006-08-24 | Kyoei Kagaku Kogyo Kk | Cosmetics |
| JP2006225269A (en) * | 2005-02-15 | 2006-08-31 | Yoshihiro Futamura | Tripeptide having collagenase inhibition, fermentation product, food preparation and cosmetic preparation containing the same |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316417A3 (en) * | 2009-09-03 | 2014-08-06 | Henkel AG & Co. KGaA | Non-therapeutic use to prevent skin aging |
| JP2011162476A (en) * | 2010-02-09 | 2011-08-25 | Maruzen Pharmaceut Co Ltd | SERINE PALMITOYLTRANSFERASE mRNA EXPRESSION PROMOTER AND AQUAPORIN 3 mRNA EXPRESSION PROMOTER |
| JP2012067061A (en) * | 2010-09-27 | 2012-04-05 | Maruzen Pharmaceut Co Ltd | Maillard reaction inhibitor and aging improving agent |
| JP2012140376A (en) * | 2010-12-29 | 2012-07-26 | Kracie Home Products Ltd | Tyrosinase activity inhibitor, melanin production inhibitor and beautifying and whitening agent, and cosmetic, food and drink composition and pharmaceutical composition each containing them |
| JP2013221017A (en) * | 2012-04-17 | 2013-10-28 | Api Co Ltd | Epidermal cell activator, cosmetic including the same, skin care external preparation and anti-wrinkle cosmetic |
| JP2016503781A (en) * | 2012-12-21 | 2016-02-08 | ロレアル | C-xyloside compound, composition thereof and use thereof for depigmenting skin |
| JP2019006731A (en) * | 2017-06-27 | 2019-01-17 | 小林製薬株式会社 | Skin cleanser composition |
| JP7036544B2 (en) | 2017-06-27 | 2022-03-15 | 小林製薬株式会社 | Skin cleanser composition |
| JPWO2021015233A1 (en) * | 2019-07-23 | 2021-01-28 | ||
| JP2025078258A (en) * | 2023-11-08 | 2025-05-20 | 株式会社山田養蜂場本社 | Dermis thickness improving agent, skin texture improving agent, and cosmetic product for improving dermis thickness or skin texture |
| JP2025078199A (en) * | 2023-11-08 | 2025-05-20 | 株式会社山田養蜂場本社 | Skin flora improving agent and skin flora improving cosmetic |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101172095A (en) | 2008-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1433463B1 (en) | Use of algal proteins in cosmetics | |
| JP5588474B2 (en) | Composition for promoting collagen and / or hyaluronic acid production | |
| CN101172095A (en) | Cosmetics material of protolysate containing royal jelly | |
| CN101111289B (en) | Anti-aging cosmetic composition | |
| US20100196302A1 (en) | Keratin Hydrolysates, Process for Their Production and Cosmetic Composition Containing the Same | |
| CN107049907A (en) | The purposes of the pancreatin zymolyte of bird's nest | |
| JPH10182412A (en) | External-use medical preparation | |
| JP5084393B2 (en) | Composition having collagen production promoting ability and / or fibroblast proliferation promoting ability | |
| KR20130108805A (en) | Cosmetic composition comprising golden silkworm(bombyx moril) derived materials as active ingredient | |
| JP2004250372A (en) | Skin aging inhibitor/improver and/or rough skin inhibitor/improver kit | |
| JP2000309521A (en) | Skin lotion | |
| CN107334718A (en) | Collagen, which produces, to be reduced inhibitor, the composition for external application and cosmetics for reducing inhibitor is produced comprising the collagen | |
| TWI601540B (en) | Human Skin Epidermal Cell Proliferator, Compositions Containing Its Skin, and Cosmetic Ingredients | |
| JP2005343887A (en) | Elastase inhibitor | |
| JP3449624B2 (en) | Method for producing cosmetics and swallow fossil extract | |
| JP6871553B2 (en) | Cosmetic composition | |
| KR101645238B1 (en) | Cosmetic composition for anti-wrinkle or elasticity of skin | |
| JP3044690B2 (en) | Cosmetics | |
| JP4916143B2 (en) | Method for producing a composition having a collagen production promoting action from an alcoholic beverage fermented with brewer's yeast and the composition | |
| JP5527917B2 (en) | Arginase activity promoter and skin external preparation containing the same | |
| JP7668036B2 (en) | Skin penetration enhancer for royal jelly | |
| JP2963136B2 (en) | Cosmetics | |
| JP2004352634A (en) | Cosmetics | |
| JP2025078258A (en) | Dermis thickness improving agent, skin texture improving agent, and cosmetic product for improving dermis thickness or skin texture | |
| JP2006290844A (en) | Cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080214 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080725 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080806 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090107 |